KDIGO Turned a Dipstick Into a Chemistry Assay

Albuminuria has been a staging axis in chronic kidney disease since the 2012 classification. The 2024 guideline did not invent it. What it did was make the quantitative version the one that counts — and a quantitative serial assay is a different business from a coloured pad.

The structural problem with urinalysis, stated plainly

A dipstick is a fixed panel. Ten or eleven pads, one price, no clinical argument for a premium version and nowhere to trade up. Compare that with clinical chemistry, where a laboratory can add an analyte, move a test from a send-out to an in-house platform, or buy a wider menu on the next analyser — every one of those being a revenue event for the vendor. Urinalysis has no such lever. Its menu is a panel and its price is one price.

That is why urinalysis behaves so differently from chemistry inside the same discipline. The 2025 disclosures make the asymmetry visible: Roche’s clinical chemistry line grew 7% inside a flat core laboratory, while Sysmex — the global urinalysis leader — saw operating profit fall 40.8% on a 1.7% revenue decline as the operating margin went from 17.2% to 10.4%. A panel business has nowhere to hide when price falls, because it has nothing to sell instead.

What the guideline actually changed

KDIGO’s 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease retains the two-axis classification: GFR category on one axis, albuminuria category on the other, combined into a risk map that determines how often the patient is monitored and how aggressively they are treated. Albuminuria is not new to that structure. What the current guideline does is insist on the measurement that produces a number — urine albumin-to-creatinine ratio on an untimed urine sample — rather than the qualitative or semi-quantitative result a dipstick returns.

Two consequences follow, and both are commercial.

First, a categorical pad result supports a yes-or-no response: protein present or absent. A UACR number supports a trend, a threshold and a staging decision. A test that produces a number gets repeated, because the number has to be shown to be moving in the right direction or not. A test that produces a colour gets repeated infrequently, because the colour tells you little that it did not tell you last time.

Second, the number is now an entry criterion for therapy rather than a supporting observation. The trials that generated the current indications for SGLT2 inhibition and for non-steroidal mineralocorticoid receptor antagonism in chronic kidney disease enrolled patients on an albuminuria threshold, not on a dipstick result. When a drug’s enrolled population is defined by an analyte value, the assay that produces that value becomes part of the treatment pathway, and the payer’s willingness to reimburse it stops being about the test and starts being about the script behind it.

Why that pulls chemistry analysers into the urinalysis workflow

An instrument that reads a strip is not an instrument that runs an immunoturbidimetric albumin assay. The measurement moved from reflectance photometry on a pad to a quantitative immunoassay on a chemistry platform — the same platform, in most laboratories, that runs creatinine. Which means the guideline’s demand signal does not land on the strip analyser at all. It lands on the chemistry analyser, in the same run as the creatinine it has to be indexed against.

That is the actual reason this cluster treats clinical chemistry and urinalysis as one market rather than two. Not because they share customers, but because the value inside urinalysis is migrating from the pad to the platform, and the platform is the chemistry analyser. Value moves off the strip without the patient population changing at all.

The arithmetic it sits inside

Our base for the combined discipline is USD 16.8 billion in 2025 to USD 22.49 billion in 2033 at 3.71%, on reportable results growing 5.13% a year — 21,540 million to 32,130 million — while realised revenue per result falls from USD 0.78 to USD 0.70. That 10.3% fall in revenue per result is the deflation story that the fee schedules and the alliances are writing.

Albumin is the one analyte inside that mix where volume and price can both move up together, because it is quantitative and guideline-anchored, and because the alternative to it — a pad — is cheaper but no longer sufficient. If guideline-driven albumin volume pushes the combined discipline’s growth toward 6% rather than 3.71%, the 2033 figure is USD 24.32 billion at 4.73%, which is our upside case. It is not an aggressive case; it is what happens if the per-result value holds instead of falling.

Three reasons the thesis could be wrong

A guideline recommendation is not a reimbursement decision. A test that is recommended and not paid for is a test that is ordered only when the clinician has another reason to order it. The US fee schedule for 2027 moves the price of chemistry downward uniformly, and nothing in it distinguishes a guideline-mandated quantitative assay from a legacy panel — which means the reimbursement environment may reward the migration with lower price rather than higher volume.

Point-of-care ACR exists. If albumin quantitation decentralises to a point-of-care device in the physician’s office, the volume grows and the chemistry analyser does not capture it. That would leave the discipline’s growth rate intact and its mix materially different from our base case.

The installed base is sticky in the wrong direction. Strip analysers are already placed and largely depreciated. A laboratory facing a 16% cut in chemistry reimbursement has a strong reason to keep using the cheaper pad it already owns. Guideline adherence in renal medicine has historically lagged the recommendation by years, and there is no reason to assume this one is different.

The marker to watch

If albumin and ACR volume does not outgrow dipstick volume across 2026 and 2027 in the disclosed laboratory volumes of the major vendors, the migration thesis is wrong and urinalysis stays a strip business with a fixed panel and a falling price. If it does outgrow it, the interesting number is not the test volume but the analyser placement mix — because that is where the value lands, and it is the number no vendor currently discloses separately.

Companion analyses in this cluster

• The First Broad Reset Since 2018 Cuts Chemistry Sixteen Per Cent — the 2027 fee schedule cut that decides whether a quantitative albumin assay is rewarded or merely permitted.
• Sysmex Took 1.7 Per Cent Off Sales and 40.8 Per Cent Off Operating Profit — the margin consequence of a panel business that has nothing to sell instead.
• Global Clinical Chemistry and Urinalysis Market Report, Size, Share and Forecast 2026-2033 — the full report, including the guideline-driven albumin sensitivity at USD 24.32bn and 4.73%.

About the method

70/30, secondary to primary. The clinical and financial claims here rest on primary documents: the KDIGO 2024 CKD guideline and its albuminuria classification tables, the underlying trials that define current CKD therapy indications, CMS’s preliminary 2027 fee schedule, and company results for Roche, Sysmex and Abbott. Our primary programme for the underlying report — 41 depth interviews across 11 markets, 26 open-ended tender interviews, a 164-respondent laboratory survey and four conferences — is used for mechanism only: why a laboratory keeps a pad assay on a placed analyser, how renal medicine adopts a guideline over years rather than quarters, and what a laboratory actually does when a quantitative assay becomes the standard of care. It carries no figure. Where the two layers disagree, the secondary layer wins and the disagreement is stated rather than smoothed. These programme parameters are stated so they can be reconciled against programme records.

Sources

• Kidney Disease: Improving Global Outcomes, KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, Kidney International 105 (Suppl 4S), April 2024 — see Table 3, albuminuria categories, and Table 4, use of GFR and albuminuria.
• Centers for Medicare & Medicaid Services, Preliminary Calendar Year 2027 Medicare Clinical Laboratory Fee Schedule Payment Rates, 21 September 2026.
• Sysmex Corporation, Consolidated Financial Results for the Fiscal Year Ended March 31, 2026, 14 May 2026.
• Roche Holding AG, Annual Report 2025; Abbott Laboratories, fourth-quarter and full-year 2025 results.

No third-party market-research estimate is used in this analysis. Guideline adoption is treated as a mechanism operating on volume and mix, not as a revenue forecast.